• # LGM Pharma is a Adalimumab CAS# 331731-18-1 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Adalimumab
  • CAS #: 331731-18-1
  • Mode of Action:

    Adalimumab binds to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the presence of complement.

  • Pharmacodynamics:

    Used in the treatment of immune system mediated diseases, adalimumab binds specifically to TNF-alpha and blocks its general cytokine effects, thereby reducing TNF-induced inflammation and halting tissue destruction.

  • Metabolism:

    Most likely removed by opsonization via the reticuloendothelial system.

  • IUPAC: Immunoglobulin G1, anti-(human tumor necrosis factor) (human monoclonal D2E7 heavy chain), disulfide with human monoclonal D2E7 light chain, dimer
  • ATC: L04AB04
  • PubChem: BTD00049
  • DrugBank: DB00051
  • Formula: C6428H9912N1694O1987
  • Molecular Mass: 144190.3
  • Synonyms: Ig gamma-1 chain C region, Adalimumab, D2E7, HSDB 7851, Humira, Immunoglobulin G1, anti-(human tumor necrosis factor), (human monoclonal D2E7 heavy chain), disulfide with human, monoclonal D2E7 light chain, dimer. Molecular weight is, approximately 148,000 daltons, LU200134, Trudexa, UNII-FYS6T7F842
  • AHFS Code: 32:00.0
  • General Reference:

     

    1. PDB sequence Link
    2. Patent Information Link
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service